3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy)pyridines: Synthesis and analgesic activity

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 6, 2005, Pages 1637-1640

  Baraznenok, Ivan L ^a   Jonsson, Emma ^a   Claesson, Alf ^b  

^a Syntagon AB   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

ABT 594; Cyclic sulfamidates; nAChR; Pyridyl ethers; Tebanicline

Indexed keywords

2 AMINOMETHYL 3 PYRROLINE; 2 HYDROXYMETHYLPYRROLINE; 3 (2,5 DIHYDRO 1H PYRROL 2 YLMETHOXY)PYRIDINE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ANALGESIC AGENT; EPIBATIDINE; ETHER; FORMALDEHYDE; PYRIDINE DERIVATIVE; SULFANILAMIDE; TEBANICLINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN;

EID: 14744269443     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.01.058     Document Type: Article

References (23)

1. T.F. Spande, H.M. Garaffo, M.W. Edwards, H.J.C. Yeh, L. Pannell, and J.W. Daly J. Am. Chem. Soc. 114 1992 3475
2. C. Qian, T. Li, T.Y. Shen, L. Libertine-Garahan, J. Eckman, T. Biftu, and S. Ip Eur. J. Pharmacol. 250 1993 R13
3. J.P. Sullivan, and A.W. Bannon CNS Drug Rev. 2 1996 21
4. D.W. Bonhaus, K.R. Bley, C.A. Broka, D.J. Fontana, E. Leung, R. Lewis, A. Shieh, and E.H.F. Wong J. Pharmacol. Exp. Ther. 273 1995 1199
5. T.S. Rao, L.D. Correa, R.T. Reid, and G.K. Lloyd Neuropharmacology 35 1996 393
6. For example, see: D. Bai, R. Xu, G. Chu, and X. Zhu J. Org. Chem. 61 1996 4600
7. E. Wright, T. Gallagher, C. Sharples, and S. Wonnacott Bioorg. Med. Chem. Lett. 7 1997 2867
8. B. Badio, H.M. Garaffo, C.V. Plummer, W.L. Padgett, and J.W. Daly Eur. J. Pharmacol. 321 1997 189
9. M.A. Abreo, N.-H. Lin, D.S. Garvey, D.E. Gunn, A.-M. Hettinger, J.T. Wasicak, P.A. Pavlic, Y.C. Martin, D.L. Donnelly-Roberts, D.J. Anderson, J.P. Sullivan, M. Williams, S.P. Arneric, and M.W. Holladay J. Med. Chem. 39 1996 817
10. A.O. Koren, A.G. Horti, A.G. Mukhin, D. Gundisch, A.S. Kimes, R.F. Dannals, and E.D. London J. Med. Chem. 41 1998 3690
11. J. Lee, C.B. Davis, R.A. Rivero, A.B. Reitz, and R.P. Shank Bioorg. Med. Chem. Lett. 10 2000 1063
12. M.W. Holladay, J.T. Wasicak, N.-H. Lin, Y. He, K.B. Ryther, A.W. Bannon, M.J. Buckley, D.J.B. Kim, M.W. Decker, D.J. Anderson, J.E. Campbell, T.A. Kuntzweiler, D.L. Donnelly-Roberts, M. Piattoni-Kaplan, C.A. Briggs, M. Williams, and S.P. Arneric J. Med. Chem. 41 1998 407
13. A.C. Kesingland, C.T. Gentry, M.S. Panesar, M.A. Bowes, J.-M. Vernier, R. Cube, K. Walker, and L. Urban Pain 86 2000 113
14. T.J. Donohoe, and P.M. Guyo J. Org. Chem. 61 1996 7664
15. F. Schieweck, and H.-J. Altenbach Tetrahedron: Asymmetry 9 1998 403
16. After several weeks at room temperature previously pure 7 contained up to 40% of the single byproduct, which was identified as 1-(tert-butoxycarbonyl)-2- methylpyrrole. We did not investigate the mechanism of this transformation
17. For example, see: B. Aguilera, and A. Fernandez-Mayoralas J. Org. Chem. 63 1998 2719
18. M. Okuda, and K. Tomioka Tetrahedron Lett. 35 1994 4585
19. L.T. Boulton, H.T. Stock, J. Raphy, and D.C. Horwell J. Chem. Soc., Perkin Trans. 1 61 1999 1421
20. D. Alker, K.J. Doyle, L.M. Harwood, and A. McGregor Tetrahedron: Asymmetry 1 1990 877
21. Selected procedures and spectral data: note
22. Enantiomerically pure S-11 and R-11 were prepared by preparative HPLC resolution of (±)-11
23. A. Tjølsen, O.-G. Berge, S. Hunskar, J.H. Rosland, and K. Hole Pain 51 1992 5